SCOPUS 정보 검색 플랫폼

British Journal of Haematology

Volumn 115, Issue 4, 2001, Pages 807-811

Complement activation plays a key role in the side-effects of rituximab treatment

(5) Van Der Kolk, L E a Grillo Lopez A J b Baars, J W c Hack, C E d Van Oers, M H J a

a ACADEMIC MEDICAL CENTER (Netherlands)

b BIOGEN (United States)

c ANTONI VAN LEEUWENHOEK HOSPITAL (Netherlands)

d CENTRAL LABORATORY (Netherlands)

Author keywords

Complement activation; Cytokines; Non Hodgkin's lymphoma; Rituximab; Side effects

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4C; COMPLEMENT INHIBITOR; CORTICOSTEROID; INTERLEUKIN 6; INTERLEUKIN 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CELL COUNT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG INFUSION; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C3C; COMPLEMENT C4; COMPLEMENT C4B; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LYMPHOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; STIMULATION, CHEMICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035676926 PISSN: 00071048 EISSN: None Source Type: Journal
DOI: 10.1046/j.1365-2141.2001.03166.x Document Type: Article

Times cited : (272)

References (26)

1
- 0027973786
- Pretreatment with divided doses of steroids strongly decreases side effects of OKT3
- (1994) Kidney International , vol.46 , pp. 1674-1679
- Bemelman, F.J.¹ Buysmann, S.² Surachno, J.³ Wilmink, J.M.⁴ Schellekens, P.T.⁵ Ten Berge, I.⁶

2
- 0031444192
- Administration of OKT3 as a two-hour infusion attenuates first-dose side effects
- (1997) Transplantation , vol.64 , pp. 1620-1623
- Buysmann, S.¹ Hack, C.E.² Van Diepen, F.³ Surachno, J.⁴ Ten Berge, I.⁵

3
- 0000419543
- PhaseI/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen
- (1999) Blood , vol.94
- Byrd, J.C.¹ Grever, M.² Davis, B.³ Lucas, M.⁴ Park, K.⁵ Goodrich, A.⁶ Morrison, C.⁷ Murphy, T.⁸ Kunkel, L.⁹ Grillo-Lopez, A.¹⁰ Waselenko, J.K.¹¹ Foon, K.A.¹²

4
- 0033016566
- Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
- (1999) Journal of Clinical Oncology , vol.17 , pp. 791-795
- Byrd, J.C.¹ Waselenko, J.K.² Maneatis, T.J.³ Murphy, T.⁴ Ward, F.T.⁵ Monahan, B.P.⁶ Sipe, M.A.⁷ Donegan, S.⁸ White, C.A.⁹

5
- 0034076307
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
- (2000) Nature Medicine , vol.6 , pp. 443-446
- Clynes, R.A.¹ Towers, T.L.² Presta, L.G.³ Ravetch, J.V.⁴

6
- 0032530342
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
- (1998) Blood , vol.92 , pp. 1927-1932
- Coiffier, B.¹ Haioun, C.² Ketterer, N.³ Engert, A.⁴ Tilly, H.⁵ Ma, D.⁶ Johnson, P.⁷ Lister, A.⁸ Feuring-Buske, M.⁹ Radford, J.A.¹⁰ Capdeville, R.¹¹ Diehl, V.¹² Reyes, F.¹³

7
- 0033067232
- Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
- (1999) Journal of Clinical Oncology , vol.17 , pp. 1851-1857
- Davis, T.A.¹ White, C.A.² Grillo-López, A.³ Velasquez, W.S.⁴ Link, B.⁵ Maloney, D.G.⁶ Dillman, R.O.⁷ Williams, M.E.⁸ Mohrbacher, A.⁹ Weaver, R.¹⁰ Dowden, S.¹¹ Levy, R.¹²

8
- 0003151121
- Treatment of chronic lymphocytic leukemia (CLL) with the anti-CD20 antibody rituximab
- (1999) Blood , vol.94
- Emmerich, B.¹ Huhn, D.² Peschel, C.³ Wilhelm, M.⁴ Von Schilling, C.⁵ Bentz, M.⁶ Hallek, M.⁷ Knauf, B.⁸ Kuse, R.⁹ Ho, A.¹⁰

9
- 0007935366
- Anti-CD20 monoclonal antibody in the treatment of post-transplant lymphoproliferative disorders (PLTD) occurring after bone marrow transplantation (BMT) in children
- (1999) Blood , vol.94
- Faye, A.¹ Quartier, P.² Lutz, P.³ Garbag-Chenon, A.⁴ Mathieu-Boue, A.⁵ Fisher, A.⁶ Vilmer, E.⁷

10
- 0034660092
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
- (2000) Blood , vol.95 , pp. 3900-3908
- Golay, J.¹ Zaffaroni, L.² Vaccari, T.³ Lazzari, M.⁴ Borleri, G.M.⁵ Bernasconi, S.⁶ Tedesco, F.⁷ Rambaldi, A.⁸ Introna, M.⁹

11
- 0027226353
- C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2
- (1993) Intensive Care Medicine , vol.19
- Hack, C.E.¹ Ogilvie, A.C.² Eisele, B.³ Eerenberg, A.J.⁴ Wagstaff, J.⁵ Thijs, L.G.⁶

12
- 0034091481
- Rituximab (Anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
- (2000) Scandinavian Journal of Immunology , vol.51 , pp. 634-641
- Harjunpaa, A.¹ Junnikkala, S.² Meri, S.³

13
- 2042447861
- IDEC Pharmaceuticals Corporation, San Diego, CA, USA
- (1997) Investigational Drug Brochure Rituximab (RituxanTM, Mab Thera, IDEC-C2B8) edition 4

14
- 2042544867
- IDEC Pharmaceuticals Corp. & Genentech Corp., San Diego, CA, USA
- (1999) USA Package Insert, revised July 1999

15
- 0026039559
- The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass
- (1991) European Journal of Cardiothoracic Surgery , vol.5 , pp. 211-217
- Jansen, N.J.¹ Van Oeveren, W.² Van Vliet, M.³ Stoutenbeek, C.P.⁴ Eysman, L.⁵ Wildevuur, C.R.⁶

16
- 0031664666
- Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 mono-clonal antibody (IDEC- C2B8, rituximab)
- (1998) Annals of Hematology , vol.77 , pp. 89-91
- Jensen, M.¹ Winkler, U.² Manzke, O.³ Diehl, V.⁴ Engert, A.⁵

17
- 4243241627
- Sargramostim/rituximab therapy for B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) patients: A toxicity profile
- (1999) Blood , vol.94
- Kleinman, M.¹ Kaplan, E.² Rhoades, D.³ Zats, S.⁴ Wechsler, J.⁵

18
- 0003262803
- Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial
- (1998) Blood , vol.92
- Van der Kolk, L.E.¹ Grillo-López, A.² Gerritsen, W.³ Baars, J.W.⁴ Van Oers, M.H.J.⁵

19
- 0345337254
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
- (1998) Journal of Clinical Oncology , vol.16 , pp. 2825-2833
- McLaughlin, P.¹ Grillo-López, A.² Link, B.K.³ Levy, R.⁴ Czuczman, M.S.⁵ Williams, M.E.⁶ Heyman, M.R.⁷ Bence-Bruckler, I.⁸ White, C.A.⁹ Cabanillas, F.¹⁰ Jain, V.¹¹ Ho, A.D.¹² Lister, J.¹³ Wey, K.¹⁴ Shen, D.¹⁵ Dallaire, B.K.¹⁶

20
- 4243985095
- Chimeric anti CD20 monoclonal antibody (rituximab) in B post-transplant lympho-proliferative disorders (B-PLTDs): A retrospective analysis on 32 patients
- (1999) Blood , vol.94
- Milpied, N.¹ Vasseur, B.² Antoine, C.³ Bouscary, D.⁴ Carret, A.⁵ Faye, A.⁶ Quartier, P.⁷ Bourbigot, D.⁸ Bourquard, P.⁹ Hurault de Ligny, B.¹⁰ Reguerre, Y.¹¹ Stoppa, A.¹² Parquet, N.¹³ Dubief, F.¹⁴ Mathieu-Boue, A.¹⁵ Leblond, V.¹⁶

21
- 0027175408
- Complement activation during OKT3 treatment: A possible explanation for respiratory side effects
- (1993) Kidney International , vol.43 , pp. 1140-1149
- Raasveld, M.H.¹ Bemelman, F.J.² Schellekens, P.T.³ Van Diepen, F.⁴ Van Dongen, A.⁵ Van Royen, E.⁶ Hack, C.E.⁷ Ten Berge, I.⁸

22
- 4243967215
- Rituximab-induced complement cascade activation is related to adverse events and bone marrow involvement
- (2000) Blood , vol.96
- Schwaner, I.¹ Von Engelhardt, L.² Jordanova, M.³ Schrewe, M.⁴ Gerecke, C.⁵ Pinkert, E.⁶ Serke, S.⁷ Huhn, D.⁸

23
- 0033214207
- Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
- (1999) Blood , vol.94 , pp. 2217-2224
- Winkler, U.¹ Jensen, M.² Manzke, O.³ Schulz, H.⁴ Diehl, V.⁵ Engert, A.⁶

24
- 0003236713
- Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab (Rituxan TM): Evaluation of safety and response
- (1999) Blood , vol.94
- Winkler, U.¹ Schulz, H.² Klein, T.³ Jensen, M.⁴ Manzke, O.⁵ Schmitz, S.⁶ Rudiger, T.⁷ Muller-Hermelink, K.⁸ Diehl, V.⁹ Engert, A.¹⁰

25
- 0003337593
- Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan TM) in patients with B-cell chronic lymphocytic leukemia: A phaseI/II study
- (1999) Blood , vol.94
- Winkler, U.¹ Schulz, H.² Jensen, M.³ Manzke, O.⁴ Rudiger, T.⁵ Muller-Hermelink, K.⁶ Diehl, V.⁷ Engert, A.⁸

26
- 0027179963
- Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway
- (1993) Journal of Immunological Methods , vol.163 , pp. 67-76
- Wolbink, G.J.¹ Bollen, J.² Ten Baars, J.W.B.R.³ Swaak, A.J.⁴ Paardekooper, J.⁵ Hack, C.E.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.